Wikipedia talk:USEP/Courses/JHU MolBio Ogg 2013/Group 81E

Choosing a WikiPedia article discussion

Hi Aaron:

Wanted to get an early start on talking about and narrowing down to eventually choose a WikiPedia article by the end of the class week. Actually even before the end of the class week. That way we allot time to working on summary explaining our rationale for our choice which has to be submitted by the end of the class week.

I say we start narrowing the topics down by doing our best to choose an article that we both have an interest in. I think that will help us enjoy the wiki assignment throughout the semester more. Of course, we'll have to have more substantial reasons for choosing the topic that we will explain in our summary, but I think this is a start like I said just to narrow down the choices.

If we choose from the 4 Wiki articles that we talked about on our group's talk page, I personally find interest in the pluripotentcy and the lysogenic cycle articles, one from each of us.

However, from what I understand from the instructions, we don't necessary have to stick to the 4 topics we shared on our group talk page. We can choose any from the list on a first come first serve basis. Let me know if this is your understanding of the instructions too. So I will add that after looking at the list of Wiki articles again, the gene duplication article caught my attention and interest.

Let me know what you think and what your interests are. Look forward to hearing from you soon. Vdiaz3 (talk) 18:56, 28 February 2013 (UTC)[reply]

Hi, Vanessa. When starting a new discussion on a talk page (like this one) you should use the "New section" link. Could you add a section header above, to fix this? Let me know if you don't understand what I'm asking you to do, by leaving a note on my talk page. Klortho (talk) 19:11, 28 February 2013 (UTC)[reply]

Thanks Klortho. Just added a heading. Vdiaz3 (talk) 20:12, 28 February 2013 (UTC)[reply]

Hi Vanessa. Thanks for the note. I like the idea of building out the pluripotency article. Apologies for the late reply to your post, in fact just read an interesting article in this month's Discover magazine about totipotency. So I'm fully in support of us pursuing pluripotency. Aaron.aude (talk) 22:23, 5 March 2013 (UTC)[reply]

Good to hear from you! I did a couple of quickly searches for pluripotency and there appears to be plenty of material. Pretty interesting stuff too and also in terms of its possible applications in research and medicine. So we agree then. Great. Pluripotency it is. For the sake of making sure we grab the topic since it is as first come, first serve deal and it is Tuesday already, I'm going to go ahead and "claim" it for our group right after I'm done writing. I guess as far as the paragraph summary with the rationale of our choice, we can put that together over email and then post it. I'll be emailing you shortly so that we can exchange ideas and put the rationale together. Vdiaz3 (talk) 23:16, 5 March 2013 (UTC)[reply]

Thanks Vanessa. I received your email, and will reply to you. Appreciate you updating the group assignments Aaron.aude (talk) 00:08, 6 March 2013 (UTC)[reply]

Vanessa. I wanted to also indicate our decision and editing process occurred via email. For Dr. Ogg, I wanted to be sure we indicated that the ideation and text creation of our rationale occurred via email. If you'd like, I can cut/paste the contents of the email into our talk thread. Please advise. Aaron.aude (talk) 02:45, 6 March 2013 (UTC)[reply]

Cell Potency Article and Content Development Discussion

Vanessa - per our Google chat this evening (4/10), here's the plan we discussed:

1. Each of us will develop 4-6 bullet points of content for our assigned sections and post them to this talk page by this Friday (4/12) . I suggest we create a section below which is called "Article Content." Specific assigned sections are as follows:

Totipotency - Aaron
Pluriopotency - Vanessa
Multipotency - Aaron
Oligopotency - Vanessa
Unipotency - Aaron / Vanessa. We'll split up and each create 2-3 bulelts

2. Develop content inside of the cell potency article and post it as it is complete. Have all content posted by Sunday evening 4/21. During this time, we'll also respond to reviewers' input on the content and adjust accordingly.

3. Review jointly developed content Monday and Tuesday 4/22 - 4/23 and edit to bring a consistent tone, voice and structure.

4. Chat/catch-up Wednesday 4/24 evening

Please feel free to correct, add/edit anything listed here.

Thanks.

65.27.246.57 (talk) 00:52, 11 April 2013 (UTC) Aaron.aude (talk) 01:13, 11 April 2013 (UTC)[reply]

Aaron, I was thinking that we could find or make a diagram going from highest degree of potency to lowest. That would put the degrees of potency in perspective with the use of a visual aid. Also, as mentioned previously, let’s make sure to step back and assess the flow as we approach the due date of our next contribution as well as look into the tone or voice of the article to make sure it sounds as if one person wrote it as well as written from an unbiased point of view. Vdiaz3 (talk) 21:48, 12 April 2013 (UTC)[reply]

Pluripotency Article Structure

Vanessa:

I've been thinking about the structure of our article - here are a few ideas/thoughts:

More structure around the summary section. This currently has little context, text and lacks any kind of intrigue.
Specific examples for each of the potency types (toti, pluri, multi, etc.)
Relevant medical examples (human, general medical relevance) to these types of cells
Consistency of voice. This article appears to be written with an inconsistent voice.
Images showing leading theories on how cells become/are induced for pluriopotency

Regarding images, there are quite a few - but most are inside of the research articles I've found. I think we should improve the current introduction image in the article with one that is more detailed. I'd also like to get a cell line table image - one that shows the types of cells associated with potency types.

Regarding the outline - I like what you have. Let's start to work on the actual text of the article - perhaps we can stub it out in the sandbox by taking the current article, cuting and pasting it on the sandbox and then working from there?

Research/Reference Article thoughts? ^[1] ^[2] ^[3] ^[4]

Sample References

^ Yamanaka S (2007). "Strategies and new developments in the generation of patient-specific pluripotent stem cells". Cell Stem Cell. 1 (1): 39–49. doi:10.1016/j.stem.2007.05.012. PMID 18371333. {{cite journal}}: Unknown parameter |month= ignored (help)
^ Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R (2003). "Multipotent cell lineages in early mouse development depend on SOX2 function". Genes Dev. 17 (1): 126–40. doi:10.1101/gad.224503. PMC 195970. PMID 12514105. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Chambers I, Colby D, Robertson M; et al. (2003). "Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells". Cell. 113 (5): 643–55. PMID 12787505. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ Gurdon JB, Byrne JA (2004). "The first half-century of nuclear transplantation". Biosci. Rep. 24 (4–5): 545–57. doi:10.1007/s10540-005-2744-5. PMID 16134025.

Aaron.aude (talk) 02:29, 14 March 2013 (UTC)[reply]

Immunolabeling

Hi, Vanessa and Aaron! I see that Vanessa is leaning more towards the pluripotency, lysogenic cycle, or gene duplication article; however, I noticed that you mention immunolabeling as a potential article for your group. Our group (group B) had some interest in the immunolabeling article, but we wanted to double-check with you two before we make our selection (if we do decide to do immunolabeling). Thank you! Jbmontgomery24 (talk) 14:36, 5 March 2013 (UTC)[reply]

Hi Jessica. That's correct. So feel free to go for it. Thanks from both of us for checking first. Vdiaz3 (talk) 23:03, 5 March 2013 (UTC)[reply]

Hi, Vanessa. Not a problem. We just made the selection a little while ago, so we thought you two were going to select one of the article ideas that you mentioned. Glad it all worked out for both groups. Best of luck to you both! Jbmontgomery24 (talk) 01:44, 6 March 2013 (UTC)[reply]

Article content

Pluripotency • Add more current research and medical uses or potential uses of iPSCs • Elaborate on the risk of iPSCs becoming tumorigenic • Elaborate on the ethical aspect of iPSCs (in relation to ESCs)

Oligopotency • Add more examples of oligopotent cells and references • Review relevance of concept of progenitor cells introduced in last sentence of this subunit; if relevant, elaborate and make the connection to oligopotency more clear

Unipotency (shared) • Add more examples of oligopotent cells and references • Investigate if the statement in the second sentence of this subunit still stands; update if necessary

Vdiaz3 (talk) 21:43, 12 April 2013 (UTC)[reply]

[ex1-1] Yamanaka S (2007). "Strategies and new developments in the generation of patient-specific pluripotent stem cells". Cell Stem Cell. 1 (1): 39–49. doi:10.1016/j.stem.2007.05.012. PMID 18371333. {{cite journal}}: Unknown parameter |month= ignored (help)

[ex2-2] Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R (2003). "Multipotent cell lineages in early mouse development depend on SOX2 function". Genes Dev. 17 (1): 126–40. doi:10.1101/gad.224503. PMC 195970. PMID 12514105. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[ex3-3] Chambers I, Colby D, Robertson M; et al. (2003). "Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells". Cell. 113 (5): 643–55. PMID 12787505. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[ex4-4] Gurdon JB, Byrne JA (2004). "The first half-century of nuclear transplantation". Biosci. Rep. 24 (4–5): 545–57. doi:10.1007/s10540-005-2744-5. PMID 16134025.

[1]

[2]

[3]

[4]